Abstract:
Abraxane: Nanoparticle platform delivers improved antitumor activity
The presentation will be on the development of nanoparticle
albumin-bound (nab™) delivery platform and the efficacy and safety
advantages of the first product, Abraxane (paclitaxel protein-bound
particles) over conventionally formulated chemotherapeutic agents. Due
in part to their small size, following IV administration the 130
nanometer particles quickly disperse as individual albumin molecules
that then carry paclitaxel to the sites of tumor. The improved
anti-tumor activity in metastatic breast cancer and a high level of
activity in other cancers (including non-small cell lung cancer,
malignant melanoma and head and neck cancers) is most likely due to the
ability of Abraxane to take advantage of the natural binding
characteristics of albumin, endogenous albumin-mediated transport
mechanisms and localization of albumin in areas of tumor due to binding
to tumor-secreted proteins.
The presentation will also include multiple other applications of the
core technology platform in the pipeline to the clinic over the next 12
to 18 months.
|
